Company profile
Arvinas, Inc.
NASDAQ: ARVN · Healthcare · Biotechnology
#266 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
61CFH 60DQ 68GM 50SS 63
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$89.4M
Rev growth YoY (TTM)
-79.1%
Net income (FY)
-$80.8M
Employees
246
as of 2026-08-11
Market cap
$580.0M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$262.6M$262.6M2025
Net income-$80.8M-$80.8M2025
Operating income-$118.5M-$118.5M2025
Total assets$717.9M$717.9M2025
Liabilities$284.0M$284.0M2025
Equity$433.9M$433.9M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
Not disclosed.
The read
What is Arvinas, Inc.’s revenue?
Arvinas, Inc. booked $262.6M in FY2025 revenue, contracting 0.3% year over year — about the middle of the pack among Healthcare companies we track, at a -30.8% net margin.
Peers · Healthcare
CareRx Corporation71BIovance Biotherapeutics, Inc.59CJushi Holdings Inc.54DTerrAscend Corp.55COmada Health62CMedical Facilities Corporation74BNeighbors
New Haven →Key facts
CEORandy Teel
SectorHealthcare
IndustryBiotechnology
HeadquartersNew Haven, CT
ExchangeNASDAQ: ARVN
Employees246
IPO date2018-09-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.